CRNX · ISSUER CIK 1658247
Crinetics Pharmaceuticals, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 11 Crinetics Pharmaceuticals, Inc. insiders reported $0.00 of open-market purchases and $0.00 of sales on SEC Form 4.
↗11 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$0.00Insider buying
$0.00Insider selling
$0.00Net open-market
Sep 1, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 202617:02 | Sep 1, 2026 | CRNX | Director | D · To issuer | $85.00 | −122,071 | 0 | -100% | $10.4M | ||
| Sep 1, 202617:02 | Sep 1, 2026 | CRNX | Director | D · To issuer | $85.00 | −19,225 | 0 | -100% | $1.6M | ||
| Sep 1, 202617:01 | Sep 1, 2026 | CRNX | Director | D · To issuer | $85.00 | −12,325 | 0 | -100% | $1.0M | ||
| Sep 1, 202617:01 | Sep 1, 2026 | CRNX | Director | D · To issuer | $85.00 | −22,225 | 0 | -100% | $1.9M | ||
| Sep 1, 202617:01 | Sep 1, 2026 | CRNX | Director | D · To issuer | $85.00 | −28,761 | 0 | -100% | $2.4M | ||
| Sep 1, 202617:00 | Sep 1, 2026 | CRNX | Director | D · To issuer | $85.00 | −22,225 | 0 | -100% | $1.9M | ||
| Sep 1, 202617:00 | Sep 1, 2026 | CRNX | Director | D · To issuer | $85.00 | −22,225 | 0 | -100% | $1.9M | ||
| Sep 1, 202616:55 | Sep 1, 2026 | CRNX | Chief Commercial Officer | D · To issuer | $85.00 | −35,669 | 0 | -100% | $3.0M | ||
| Sep 1, 202616:54 | Sep 1, 2026 | CRNX | Chief Scientific Officer | D · To issuer | $85.00 | −137,936 | 0 | -100% | $11.7M | ||
| Sep 1, 202616:53 | Sep 1, 2026 | CRNX | Chief Financial & Infra. Ofcr. | D · To issuer | $85.00 | −79,427 | 0 | -100% | $6.8M | ||
| Sep 1, 202616:52 | Sep 1, 2026 | CRNX | President & CEO, Director | D · To issuer | $85.00 | −1,402,911 | 0 | -100% | $119.2M | ||
| Aug 24, 202616:52 | Aug 20, 2026 | CRNX | Chief Financial & Infra. Ofcr. | A · Grant | — | +471 | 79,427 | +1% | — | ||
| Aug 11, 202616:11 | Aug 7, 2026 | CRNX | President & CEO, Director | M · Exercise | $20.07 | +19,928 | 424,706 | +5% | $400K |